16 September 2026 editorial review · Trial
OPT101 Phase 1b in adults with type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Registry-posted Cpeptide(.03/.07/.16ng/mL),HbA1c(.53/.12/.06) andrelatedAE(1/1/0) tables checked by group; no efficacy established. Some registry fields repeat values/labels inconsistently; not corrected by inference.
Registry: NCT05428943. Endpoint reviewed: Number of Treatment-related AE's as Assessed by CTCAE v4.0 (42 days). Eligibility reviewed: Age 18 Years to 60 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Results access: Actual posted primary/secondary outcome tables were read, including denominator, group labels and estimates. No peer-reviewed status is inferred from posting.